Premium
Comparative Efficacy and Effectiveness: An Opportunity for Clinical Pharmacology
Author(s) -
Lalonde R L,
Willke R J
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.240
Subject(s) - clinical pharmacology , reimbursement , pharmacology , drug development , medicine , drug , health care , alternative medicine , public economics , intensive care medicine , actuarial science , business , economics , economic growth , pathology
Over the past 10 or more years, the drug development paradigm has shifted radically as a consequence of the availability of generic formulations for many important drugs and the growing influence of major payers in controlling reimbursement of new medicines. The demand for health care in an aging and increasingly information‐seeking population is steadily outstripping society's ability to pay for all possible treatments. Regulatory approval of new drugs is necessary but no longer sufficient for market access in many countries, including the United States. Clinical Pharmacology & Therapeutics (2011) 90 6, 761–763. doi: 10.1038/clpt.2011.240